5 recruiting. 4 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 4 |
| Phase 4 | 1 | Recruiting 1 |
Follow Vaxneuvance: new trials by email Literature Review of Vaxneuvance trials Research Report on Vaxneuvance
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age Investigational varicella vaccine, Marketed varicella vaccine, MMR vaccine - Chickenpox | Phase 3 | Recruiting | GlaxoSmithKline | 600 | 2025-05-15 | 2026-05-29 |
| A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age Candidate varicella vaccine, Marketed varicella vaccine, MMR vaccine - Chickenpox | Phase 3 | Recruiting | GlaxoSmithKline | 911 | 2025-04-17 | 2026-05-29 |
| Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15 PCV15, Streptococcus pneumoniae serotype 3, Placebo - Pneumococcal Disease, Pneumococcal Carriage | Phase 4 | Recruiting | University of Oxford | 106 | 2025-02-24 | 2025-04-15 |
| A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investigational varicella vaccine_Lot 3 - Chickenpox | Phase 3 | Recruiting | GlaxoSmithKline | 1840 | 2025-01-10 | 2026-05-29 |
| A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine - Chickenpox | Phase 3 | Recruiting | GlaxoSmithKline | 750 | 2024-11-26 | 2026-05-29 |
Chickenpox (4) · Pneumococcal Infections (1)
GlaxoSmithKline (4) · University of Oxford (1)
Estonia (3) · Poland (3) · United States (3) · Belgium (2) · Dominican Republic (2) · Mexico (2) · Thailand (2) · Bulgaria (1) · Colombia (1) · Czechia (1) · Denmark (1) · Greece (1) · Honduras (1) · Hong Kong (1) · Lithuania (1)
Daniela M Ferreira, PhD (1) · Simon Drysdale, MRCPCH, PhD, PgDip PID, FRCPH (1)